2019 novel coronavirus: what is currently known, cardiovascular implications and management.

2019 novel coronavirus: what is currently known, cardiovascular implications and management. Minerva Cardioangiol. 2020 May 29;: Authors: Cappannoli L, Scacciavillani R, Iannaccone G, Anastasia G, Di Giusto F, Crea F Abstract From first cases reported on December 31, 2019, in Wuhan, Hubei-China, SARS-CoV2 has spread worldwide and finally the World Health Organization declared the pandemic status. We summarize what makes SARS-CoV2 different from previous highly pathogenic coronaviruses and why it is so contagious, with focus on its clinical presentation and diagnosis, which is mandatory to start the appropriate management and reduce the transmission. As far as infection pathophysiology is still not completely clarified, this review focuses also on the cardiovascular (CV) implication of COVID-19 and the capability of this virus to cause direct myocardial injury, myocarditis and other CV manifestations. Furthermore, we highlight the relationship between the virus, enzyme ACE2 and ACE inhibitors. Clinical management involves the intensive care approach with intubation and mechanical ventilation in the most serious cases and drug therapy with several apparently promising old and new molecules. Aim of this review is then to summarize what is actually known about the SARS-CoV2 and its cardiovascular implications. PMID: 32472991 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Related Links:

AbstractCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a global pandemic with the highest number of affected individuals in the modern era. Not only is the infection inflicting significant morbidity and mortality, but there has also been  a significant strain to the health care system and the economy. COVID-19 typically presents as viral pneumonia, occasionally leading to acute respiratory distress syndrome (ARDS) and death. However, emerging evidence suggests that it has a significant impact on the cardiovascular (CV) system by di rect myocardial da...
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
Abstract The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mort...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research
CONCLUSIONS: Rapidly emerging data on coronavirus disease 2019, together with results from studies on severe acute respiratory syndrome coronavirus-1, are providing insight into how endothelial dysfunction may contribute to the pandemic that is paralyzing the globe. This may, in turn, inform the design of biomarkers predictive of disease course, as well as therapeutics targeting pathogenic endothelial responses. PMID: 32510978 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Tags: Arterioscler Thromb Vasc Biol Source Type: research
CONCLUSIONS: Further studies are required in order to establish the complicated association between SARS-CoV-2 infection and its effects on the cardiovascular system. Our knowledge regarding diagnostic approaches, therapeutic management and preventive measures is constantly enriched throughout an abundance of ongoing research in the respective fields. PMID: 32472990 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
The novel coronavirus 2 (SARS-CoV-2) was first described in Wuhan, China, in December 2019, and causes the infectious disease; COVID-19, which has been declared a pandemic by the World Health Organization. COVID-19 pneumonia may lead to acute respiratory distress syndrome and severe respiratory failure [1]. Other complications include myocarditis, renal failure and neurological involvement [2].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
We present a clinical-pathological correlation report of a previously healthy Hispanic woman with laboratory-confirmed COVID-19 who had typical features of acute respiratory distress syndrome (ARDS), and also showed cardiac abnormalities thought to represent fulminant viral myocarditis. Congruent with the ARDS clinical impression, autopsy findings were remarkable for extensive and markedly severe acute lung injury consistent with viral pneumonia, characterized by diffuse alveolar damage, pulmonary infarction, severe pulmonary edema, desquamation of pneumocytes with intraalveolar aggregation, and pneumocyte morphological al...
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
Coronavirus disease 2019 (COVID-19), characterized by acute respiratory failure and multiple organs damages, has been becoming a pandemic disease around the world since December 2019. The pathogen induced COVID-19 is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1, 2. According the data from the World Health Organization (WHO), by 27 April, 2020, there have been 2,883,603 confirmed cases of COVID-19 with 198,842 deaths3. Although respiratory failure is the main clinical character of COVID-19 patients, quite a few patients developed cardiovascular diseases, such as cardiac arrest, myocarditis and arrhythmia4.
Source: Heart and Lung - Category: Intensive Care Authors: Tags: Letters to the Editor Source Type: research
Abstract Coronaviruses (CoVs) possess an enveloped, single, positive-stranded RNA genome which encodes for four membrane proteins, namely spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins 3-5 [1]. With regard to pathogenicity, S proteins are essential for viral entry into host cells [2, 3]. SARS-CoV binds to the angiotensin-converting enzyme (ACE)2 which is present on nonimmune cells, such as respiratory and intestinal epithelial cells, endothelial cells, kidney cells (renal tubules) and cerebral neurons and immune cells, such as alveolar monocytes/macrophages [4-6]. Of note, CD209L or liver/lymp...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Endocrinology Authors: Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Abstract Coronavirus Disease 2019 (COVID-19) is a rapidly expanding global pandemic due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) resulting in significant morbidity and mortality. A substantial minority of patients hospitalized develop an Acute COVID-19 Cardiovascular Syndrome (ACovCS) that can manifest with a variety of clinical presentations, but often presents as an acute cardiac injury with cardiomyopathy, ventricular arrhythmias and hemodynamic instability in the absence of obstructive coronary artery disease. The etiology of this injury is uncertain, but is suspected to be related to my...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
AbstractThe ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as  air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can resul t in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
More News: Cardiology | Cardiovascular | China Health | Coronavirus | COVID-19 | Heart | Intensive Care | International Medicine & Public Health | Myocarditis | Pandemics | SARS | WHO